Last reviewed · How we verify
CD70-CAR-NK Cell Therapy for T Cell Lymphoma and Acute Myeloid Leukemia
CD70 is a promising target for immunotherapy because it is overexpressed in T-cell lymphoma (TCL) and acute myeloid leukemia (AML) tumor cells but is found in deficient levels in normal tissues and hematopoietic stem cells. This study aims to evaluate the safety and efficacy of CD70-targeted CAR-NK (CD70-CAR-NK) cells in patients with relapsed and refractory TCL and AML.
Details
| Lead sponsor | Second Affiliated Hospital, School of Medicine, Zhejiang University |
|---|---|
| Phase | PHASE1 |
| Status | NOT_YET_RECRUITING |
| Enrolment | 25 |
| Start date | Sun Dec 01 2024 00:00:00 GMT+0000 (Coordinated Universal Time) |
| Completion | Thu Nov 30 2028 00:00:00 GMT+0000 (Coordinated Universal Time) |
Conditions
- Relapsed/refractory T-cell Lymphoma
- Relapsed/refractory Acute Myeloid Leukemia
Interventions
- CD70 CAR-NK